Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 23% Improvement Relative Risk c19early.org/o Topless et al. Colchicine for COVID-19 Prophylaxis Is prophylaxis with colchicine beneficial for COVID-19? Retrospective 341,398 patients in the United Kingdom Lower mortality with colchicine (not stat. sig., p=0.12) Topless et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(21)00401-X Favors colchicine Favors control
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study
Topless et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(21)00401-X
Topless et al., Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study, The Lancet Rheumatology, doi:10.1016/S2665-9913(21)00401-X
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
UK Biobank retrospective showing a higher risk of COVID-19 cases and mortality for patients with gout. Among patients with gout, mortality risk was lower for those on colchicine, OR 1.06 [0.60-1.89], compared to those without colchicine, OR 1.38 [1.08-1.76].
risk of death, 23.2% lower, OR 0.77, p = 0.12, relative odds for patients with gout, model 2, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Topless et al., 28 Jan 2022, retrospective, database analysis, United Kingdom, peer-reviewed, 6 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Articles Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study Ruth K Topless, Angelo Gaffo, Lisa K Stamp, Philip C Robinson, Nicola Dalbeth, Tony R Merriman Summary Lancet Rheumatol 2022; 4: e274–81 Published Online January 28, 2022 https://doi.org/10.1016/ S2665-9913(21)00401-X See Comment page e233 Biochemistry Department, University of Otago, Dunedin, New Zealand (R K Topless BSc, Prof T R Merriman PhD); Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA (A Gaffo MD, Prof T R Merriman); Birmingham Veteran Affairs Medical Center, Birmingham, AL, USA (A Gaffo); University of Otago Christchurch, Christchurch, New Zealand (Prof L K Stamp PhD); University of Queensland, Brisbane, QLD, Australia (P C Robinson PhD); Department of Medicine, University of Auckland, Auckland, New Zealand (Prof N Dalbeth MD) Correspondence to: Prof Tony R Merriman, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA tony.merriman@otago.ac.nz Background There is a paucity of data on outcomes for people with gout and COVID-19. We aimed to assess whether gout is a risk factor for diagnosis of COVID-19 and COVID-19-related death, and to test for sex- and drug-specific differences in risk. Methods We used data from the UK Biobank, which included 15 871 people with gout. We used multivariable-adjusted logistic regression in the following analyses using a case-control study design: to test for an association between gout and COVID-19 diagnosis in the entire UK Biobank cohort (n=459 837); to test for an association between gout and COVID-19-related death in people who were known to have died or survived with COVID-19 (n=15 772); to test for an association between gout and COVID-19-related death in the entire UK Biobank cohort (n=459 837); and to assess risk of COVID-19-related death in a subset of patients from the UK Biobank cohort with prescription data, stratified by prescription of urate-lowering therapy and colchicine (n=341 398). Models 1 and 2 were adjusted for age group, sex, ethnicity, Townsend deprivation index, BMI, and smoking status. Model 2 was also adjusted for diagnosis of 16 other diseases that are established comorbidities of gout or established risk factors for COVID-19-related death. Findings Gout was associated with diagnosis of COVID-19 (odds ratio [OR] 1·20, 95% CI 1·11–1·29) but not with risk of COVID-19-related death in the cohort of patients diagnosed with COVID-19 (1·20, 0·96–1·51). In the entire cohort, gout was associated with COVID-19-related death (1·29, 1·06–1·56); women with gout had an increased risk of COVID-19-related death (1·98, 1·34–2·94), whereas men with gout did not (1·16, 0·93–1·45). We found no significant differences in the risk of COVID-19-related death according to prescription of urate-lowering therapy or colchicine. When patients with gout were stratified by vaccination status, the risk of diagnosis with COVID-19 was significant in the non-vaccinated group (1·21, 1·11–1·30) but not the vaccinated group (1·09, 0·65–1·85). Interpretation Gout is a risk factor for COVID-19-related death in the UK Biobank cohort, with an increased risk in women with gout, which was driven by risk factors independent of the metabolic comorbidities of gout. Funding Health Research Council of New Zealand. Copyright © 2022 Elsevier Ltd. All rights reserved.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit